Opendata, web and dolomites

GI-BCT SIGNED

Disruptive imaging technology for accurate and painless breast cancer diagnosis

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 GI-BCT project word cloud

Explore the words cloud of the GI-BCT project. It provides you a very rough idea of what is the project "GI-BCT" about.

survival    68    gratxray    saving    400    avoiding    unnecessary    revenue    640    lowering    precise    mammography    ready    clinical    tomography    yielding    interferometry    patents    prevalent    reduce    59    portfolio    estimate    tissue    investment    routing    missed    commercialization    size    worked    environment    profits    provides    56    potentially    painless    2021    85b    contracts    procedure    employees    first    net    outcomes    scientific    start    computed    solid    agents    95    detection    207    images    stage    recalls    5m    patients    die    15    save    women    hired    breasts    form    centers    contrast    bct    efficient    natural    patient    granted    sold    disruptive    entering    therapeutic    compression    gi    formed    market    performing    disease    machinery    resolution    team    later    cancer    discrimination    scanned    imaging    industry    rate    positives    treatment    service    roi    beur    2d    breast    meur    false    healthcare    3d    grating    programs    painful    patent    countries    dense    limited    sales    discovered    amount    21    poor    mortality    screening    produces    combines    trials    q1    demonstrated   

Project "GI-BCT" data sheet

The following table provides information about the project.

Coordinator
GRATXRAY AG 

Organization address
address: PARK INNOVAARE
city: VILLIGEN
postcode: 5234
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Switzerland [CH]
 Project website https://www.gratxray.com/
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2018
 Duration (year-month-day) from 2018-05-01   to  2018-08-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    GRATXRAY AG CH (VILLIGEN) coordinator 50˙000.00

Map

 Project objective

Breast cancer is the most prevalent form of cancer in women, as 1 in 9 women are affected and 1 in 30 will die from the disease. Early detection is essential to reduce the mortality, thus countries have established routing screening programs. The problem is that main screening procedure of mammography is painful for patients, produces high rate of false positives for women with dense breast tissue, provides limited contrast, low-resolution and poor tissue discrimination properties. False positives lead to performing unnecessary therapeutic procedures. Also cancer in dense breasts is missed out by mammography, lowering survival outcomes when discovered in later stage. GratXray is entering the 3,56 BEUR size breast imaging market with our disruptive grating interferometry-based breast computed tomography – GI-BCT technology. GI-BCT will provide painless, efficient and precise breast cancer imaging. The breast will be scanned in its natural state in 3D, without compression and contrast agents, yielding images with a much higher contrast and better resolution. Thus saving €1,85B in healthcare costs in Europe and US by avoiding recalls, €640 000 from machinery costs for breast centers and potentially save treatment costs in the amount of €95 000 per patient. We have worked for the past 15 years in GI-BCT research and have a solid patent portfolio of 8 granted patents. Currently, we have demonstrated our technology in operational environment, and we are ready to start first clinical trials in 2D with the goal to make first sales in Q1 2021. We have formed a team that combines strong scientific, industry and user know-how. We estimate that a further investment of €5M and 3 years is required to reach the commercialization stage. We estimate that in year 6 we have hired 50 employees, sold 59 systems per year, have 207 service contracts, revenue of 68 MEUR, net profits of 21 MEUR and reach ROI of 4 (400%).

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "GI-BCT" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "GI-BCT" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

CoLumbo (2019)

AUTOMATED DIAGNOSTICS AND RADIOLOGICAL READING FROM LUMBAR SPINE MRI

Read More  

ClosedToe (2020)

Sock toe closing system for circular knitting machines

Read More  

COPI (2020)

Carbon Offset Plug-in

Read More